AMLX compared with RLAY: revenue, margins and what each company keeps, and the suppliers and customers both name

AMLXAmylyx Pharmaceuticals, Inc.

Mkt capRevenueRevenue

RLAYRelay Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMLXAmylyx Pharmaceuticals, Inc.

RLAYRelay Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AMLX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±25.6%▲+10.71%×0.42

May 7 '26±11.9%▼−5.35%×0.45

Q1 FY26±17.6%▼−7.78%×0.44

Nov 6 '25±18.9%▼−5.89%×0.31

RLAY

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.0%▲+0.10%×0.01

May 6 '26±14.2%▼−0.62%×0.04

= impliedAMLX realized, solidRLAY realized, hatchedOne scale, both sides: full bar = 41%× = |realized| ÷ impliedSource: market data

Q1 FY26

±40.7%

▲+12.01%

×0.29

Q3 FY25±32.5%▼−7.35%×0.22

AMLXAmylyx Pharmaceuticals, Inc.

28.86▲+0.63%· post 29.02

Mkt cap$3.2BRevenue$416,000Q3 FY24

RLAYRelay Therapeutics, Inc.

18.35▼−5.78%· post 18.35

ClosedOct 30 '26

Mkt cap$4.0BRevenue$350,000Q2 FY26

Compare

ClosedOct 30 '26

AMLXAmylyx Pharmaceuticals, Inc.

RLAYRelay Therapeutics, Inc.

28.86▲+0.63%post 29.02

Price

18.35▼−5.78%post 18.35

$3.2B

Mkt cap

$4.0B

Q3 FY24$416,000

Revenue

$350,000Q2 FY26

AMLX28.86▲+0.63%vsRLAY18.35▼−5.78%ClosedOct 30 '26